Connect with us on the social channels
Press Releases
Dr Ada Kruisbeek resigns as CSO, assumes role as Chair of the Scientific Advisory Board
Leiden, The Netherlands, January 2019 – DCprime announces that Dr Ada Kruisbeek, founder, CSO and former CEO of the company, has resigned from her acting role as CSO per January 1, 2019. DCprime has appointed Dr Kruisbeek as Chair of the company’s Scientific Advisory Board. Dr Kruisbeek founded DCprime in
DCprime announces first patient dosed in phase 2 ADVANCE-II study with DCP-001 in patients with Acute Myeloid Leukemia
Leiden, The Netherlands, 15 November 2018 – DCprime bv, a clinical stage biotechnology company focused on cancer immunotherapies, announces that the first patient has been dosed with DCP-001 in a phase 2 study, called ADVANCE-II. Patients with Acute Myeloid Leukemia (AML) in complete remission after induction therapy but
Jeroen Rovers MD, PhD joins DCprime as Chief Medical Officer
Leiden, The Netherlands, October 01, 2018 – DCprime announces today that Jeroen Rovers MD, PhD joins the company as its Chief Medical Officer with immediate effect. Jeroen trained as a pharmaceutical physician at the European Center of Pharmaceutical Medicine in Basel. In the past 15 years he worked in different
Clinical study data of DCP-001 in AML published in leading journal for new concepts and advances in cancer immunology and immunotherapy
Clinical study data of DCP-001 in AML published in leading journal for new concepts and advances in cancer immunology and immunotherapy. Leiden, The Netherlands, 26 July 2018 – DCprime announces that the results of the phase I study with its lead product DCP-001 in AML have been published in Cancer
DCprime and Glycotope announce licensing agreement and collaboration
DCprime and Glycotope announce licensing agreement and collaboration Leiden, The Netherlands, and Berlin, Germany, 18 July 2018 – DCprime bv, a clinical stage biotechnology company focused on cell-based cancer vaccines, and Glycotope GmbH, a clinical stage immuno-oncology company built on world-leading glycobiology expertise, announce today that they have
DCprime announces that Erik Manting PhD will join the company as its CEO
Leiden, The Netherlands, March 01, 2018 – DCprime announces today that Erik Manting PhD will become DCprime’s new Chief Executive Officer with immediate effect. Dr Manting succeeds Ada Kruisbeek, who will remain committed to DCprime as Chief Scientific Officer. Prior to joining DCprime, Erik spent 15 years in different management
DCOne® induces immune responses against Multiple Myeloma
Leiden, The Netherlands – DCPrime B.V., a clinical stage company dedicated to developing cancer vaccines based on its proprietary DCOne® platform, announces the publication of a peer-reviewed research paper which documents that its lead product DCP-001 can induce T cell activation and myeloma-specific immunity in peripheral blood mononuclear cells from